22-10-2020
Pavel Kapysh / Shutterstock.com
US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Seagen, Daiichi Sankyo, breast cancer, Enhertu, AstraZeneca, ADCs, cells, FDA
PTAB grants review of Seagen patent on eve of court’s infringement ruling
11-04-2022
Pyxis secures ADC licence from Pfizer
22-03-2021
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18-11-2020
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30-07-2020
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12-02-2020
